Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| EXAS | EXACT SCIENCES CORP | 2026-02-17 19:14:56 | 103.2 | -0.11 | -0.11 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EXAS | 0001124140 | EXACT SCIENCES CORP | US30063P1057 | 549300VM3X1FYD4N9Z14 | 200478229 | Nasdaq | 8071 | Services-Medical Laboratories | 1231 | DE | 5505 ENDEAVOR LANE | MADISON | WI | 53719 | UNITED STATES | US | 608-284-5700 | 5505 ENDEAVOR LANE, MADISON, WI, 53719 | 5505 ENDEAVOR LANE, MADISON, WI, 53719 | EXACT CORP | — | 1995 | Kevin Conroy | 6,500 | http://exactsciences.com | 7,726,320,579 | 189,452,459 | 189,471,298 | Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer. | 2026-02-12 15:48:00 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 7,726,320,579 | -9,070,030,559 | -54.0 | 185,755,406 | 4,224,439 | 2.3271 |
| 2023 | 16,796,351,138 | 9,891,286,107 | 143.2468 | 181,530,967 | 3,313,825 | 1.8594 |
| 2021 | 6,905,065,031 | -5,996,087,023 | -46.4771 | 178,217,142 | 9,123,980 | 5.3958 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Elliott | Chief Financial Officer, Executive Vice President | 2024 | 392,176 | 0 | 273,173 | 0 | 2,556,092 | 3,221,441 |
| Jacob Orville | Executive Vice President | 2024 | 618,000 | 0 | 3,581,298 | 202,812 | 31,082 | 4,433,192 |
| Kevin Conroy | Chief Executive Officer, Chairman, President | 2024 | 1,083,368 | 0 | 13,496,138 | 712,329 | 247,543 | 15,539,378 |
| Aaron Bloomer | Chief Financial Officer, Executive Vice President | 2024 | 431,868 | 600,000 | 6,002,837 | 136,662 | 15,421 | 7,186,788 |
| Brian Baranick | Executive Vice President | 2024 | 600,400 | 0 | 3,581,298 | 196,980 | 20,990 | 4,399,668 |
| Fiscal Year | Employee Count |
|---|---|
| 2019 | 4,110 |
| 2012 | 87 |
| 2011 | 61 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 3,246,990,000 | 2,758,867,000 | 2,499,766,000 |
| Cost Of Revenue | 984,235,000 | 840,150,000 | 654,248,000 |
| Gross Profit | 2,262,755,000 | 1,918,717,000 | — |
| Research And Development Expenses | 522,996,000 | 431,210,000 | 425,882,000 |
| General And Administrative Expenses | 888,674,000 | 781,825,000 | 893,204,000 |
| Operating Expenses | 2,469,053,000 | 2,976,620,000 | 2,793,205,000 |
| Operating Income | -206,298,000 | -1,048,703,000 | -215,012,000 |
| Net Income | -207,949,000 | -1,028,857,000 | -204,149,000 |
| Earnings Per Share Basic | -1.1 | -5.59 | -1.13 |
| Earnings Per Share Diluted | -1.1 | -5.59 | -1.13 |
| Weighted Average Shares Outstanding Basic | 188,688,000 | 184,197,000 | 180,144,000 |
| Weighted Average Shares Outstanding Diluted | 188,688,000 | 184,197,000 | 180,144,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 955,996,000 | 600,889,000 | 605,378,000 |
| Marketable Securities Current | 8,715,000 | 437,137,000 | 172,266,000 |
| Accounts Receivable | 298,653,000 | 248,968,000 | 203,623,000 |
| Inventories | 166,201,000 | 162,383,000 | 127,475,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 1,555,849,000 | 1,571,423,000 | 1,194,369,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 708,664,000 | 693,673,000 | 698,354,000 |
| Other Assets Non Current | 185,811,000 | 169,722,000 | 177,387,000 |
| Total Assets Non Current | 4,304,780,000 | 4,356,716,000 | 5,276,965,000 |
| Total Assets | 5,860,629,000 | 5,928,139,000 | 6,471,334,000 |
| Accounts Payable | 175,868,000 | 89,572,000 | 78,816,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 15,220,000 | 37,765,000 | 14,823,000 |
| Total Liabilities Current | 641,152,000 | 732,187,000 | 514,701,000 |
| Long Term Debt | — | — | 50,000,000 |
| Other Liabilities Non Current | 329,317,000 | 315,503,000 | 335,982,000 |
| Total Liabilities Non Current | 2,818,425,000 | 2,793,703,000 | 2,811,328,000 |
| Total Liabilities | 3,459,577,000 | 3,525,890,000 | 3,326,029,000 |
| Common Stock | 1,909,000 | 1,857,000 | 1,815,000 |
| Retained Earnings | -4,705,981,000 | -4,498,032,000 | -3,469,175,000 |
| Accumulated Other Comprehensive Income | 2,358,000 | -944,000 | 1,428,000 |
| Total Shareholders Equity | 2,401,052,000 | 2,402,249,000 | 3,145,305,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 124,879,000 | 119,701,000 | — |
| Share Based Compensation Expense | 217,666,000 | 214,885,000 | 231,312,000 |
| Other Non Cash Income Expense | -6,896,000 | 519,000 | — |
| Change In Accounts Receivable | 48,891,000 | 46,259,000 | 43,416,000 |
| Change In Inventories | 3,772,000 | 34,911,000 | 7,690,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 5,794,000 | 2,323,000 | 11,618,000 |
| Change In Accounts Payable | 214,042,000 | 43,538,000 | 82,750,000 |
| Change In Other Liabilities | -5,219,000 | 9,726,000 | 6,333,000 |
| Cash From Operating Activities | 491,438,000 | 210,536,000 | 156,119,000 |
| Purchases Of Marketable Securities | 140,269,000 | 465,031,000 | 139,854,000 |
| Sales Of Marketable Securities | 572,277,000 | 205,821,000 | 363,156,000 |
| Acquisition Of Property Plant And Equipment | 134,656,000 | 135,989,000 | 124,190,000 |
| Acquisition Of Business | 0 | 0 | 52,413,000 |
| Other Investing Activities | -297,000 | 225,000 | -250,000 |
| Cash From Investing Activities | 195,121,000 | -442,155,000 | 49,679,000 |
| Tax Withholding For Share Based Compensation | 86,477,000 | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 26,544,000 | 31,227,000 | 28,344,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | -11,887,000 | -17,754,000 | -9,751,000 |
| Cash From Financing Activities | -338,090,000 | 231,874,000 | 159,766,000 |
| Change In Cash | 349,360,000 | -3,039,000 | 366,885,000 |
| Cash At End Of Period | 955,996,000 | 600,889,000 | 605,378,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 30,444,000 | 27,839,000 | 18,776,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.1 | -5.59 | -1.13 |
| Price To Earnings Ratio | -92.3273 | -10.0519 | -65.469 |
| Earnings Growth Rate | -80.322 | 394.6903 | -67.5287 |
| Price Earnings To Growth Ratio | 1.1495 | -0.0255 | 0.9695 |
| Book Value Per Share | 12.725 | 13.0417 | 17.4599 |
| Price To Book Ratio | 7.9811 | 4.3085 | 4.2371 |
| Ebitda | -50,204,000 | -886,842,000 | — |
| Enterprise Value | — | — | 12,771,675,120 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | 0.0159 |
| Capital Expenditures | 139,870,000 | 115,020,000 | — |
| Free Cash Flow | 351,568,000 | 95,516,000 | — |
| Return On Equity | -0.0866 | -0.4283 | -0.0649 |
| One Year Beta | 0.7512 | 0.4312 | 1.7134 |
| Three Year Beta | 0.9101 | 1.5114 | 1.6075 |
| Five Year Beta | 1.2596 | 1.2482 | 1.3396 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Bloomer Aaron | EVP, Chief Financial Officer | 2025-12-23 | 38,715 | A | 52,338 |
| Bloomer Aaron | EVP, Chief Financial Officer | 2025-12-23 | 17,151 | D | 35,187 |
| Bloomer Aaron | EVP, Chief Financial Officer | 2025-12-23 | 24,384 | A | 59,571 |
| Bloomer Aaron | EVP, Chief Financial Officer | 2025-12-23 | 10,803 | D | 48,768 |
| Bloomer Aaron | EVP, Chief Financial Officer | 2025-12-23 | 38,715 | D | 0 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Josh Gottheimer | 2024-06-08 | NJ05 | Sale | 2024-05-10 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2024-03-07 | NJ05 | Sale (Partial) | 2024-02-01 | Joint | $1,001 - $15,000 |
| Kevin Hern | 2024-02-11 | OK01 | Sale | 2024-01-02 | Child | $1,001 - $15,000 |
| Josh Gottheimer | 2023-12-08 | NJ05 | Sale (Partial) | 2023-11-13 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2023-11-11 | NJ05 | Purchase | 2023-10-16 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| TWO SIGMA ADVISERS, LP | 2025-12-31 | 1,315,811 | 12,956 | 101.56 |
| SageView Advisory Group, LLC | 2025-12-31 | 81,859 | 806 | 101.562 |
| FMR LLC | 2025-12-31 | 117,257,981 | 1,154,568 | 101.56 |
| DSC Meridian Capital LP | 2025-12-31 | 8,357,068 | 82,287 | 101.56 |
| AMERIPRISE FINANCIAL INC | 2025-12-31 | 174,476,168 | 1,717,958 | 101.5602 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| BAIRD FUNDS INC | 2025-12-31 | Institutional Class | BSGIX | 32,568 | 3,307,606.08 | 3.3312 |
| BAIRD FUNDS INC | 2025-12-31 | Investor Class | BSGSX | 32,568 | 3,307,606.08 | 3.3312 |
| Global X Funds | 2025-11-30 | Global X Aging Population ETF | AGNG | 9,639 | 976,334.31 | 1.2851 |
| Invesco Exchange-Traded Fund Trust II | 2025-11-30 | Invesco Russell 1000 Equal Weight ETF | EQAL | 10,858 | 1,099,806.82 | 0.1587 |
| UNIFIED SERIES TRUST | 2025-11-30 | OneAscent Enhanced Small and Mid Cap ETF | OASC | 4,953 | 501,689.37 | 0.7369 |